Coronary Heart Disease – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the diagnosed incidence and prevalence of CHD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s CHD forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of CHD?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CHD over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four CHD patient populations, as follows:
- Diagnosed prevalent cases of CHD.
- Diagnosed prevalent cases of CHD with stable angina.
- Diagnosed prevalent cases of CHD without stable angina.
- Diagnosed incident cases of CHD.
Note: Coverage may vary by country.
